Earnings ·
Kura Oncology reports $9.1M in second-quarter KOMZIFTI revenue, up 57% from first quarter
KURAKura Oncology, Inc.
Kura Oncology, Inc. reported second quarter 2026 financial results on August 12, 2026. Net product revenue from KOMZIFTI (ziftomenib) reached $9.1 million, a 57% increase from the first quarter, driven by approximately 115 new patient starts and over 250 total prescriptions. The company reported a net loss of $68.3 million compared to $66.1 million in the prior year period. As of June 30, 2026, Kura held $519.0 million in cash, cash equivalents, and short-term investments, supplemented by $180 million in anticipated collaboration payments from Kyowa Kirin. The company provided clinical updates on ziftomenib's frontline AML potential and darlifarnib's activity in solid tumors. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer.